MARKET NEWS

VYNE Therapeutics Announces Positive Phase 1b Efficacy Data From Phase 1b/2a Trial 
Rhythm Pharmaceuticals Optimizes Design of EMANATE & DAYBREAK Clinical Trials to Advance Setmelanotide for Rare Genetic Diseases of Obesity
Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp & Body Psoriasis
Sterling Pharma Solutions Expands Capabilities & Laboratory Capacity
Processa Pharmaceuticals Announces First Patient Enrolled in Phase 2A Trial for the Treatment of Gastroparesis
Agenus’ CD137 Agonist Advances in the Clinic, Triggering Milestone Payment From Gilead

  FEATURED EDITORIAL

 

  COMPANY PROFILE

With over 70 years of proven experience, Aptar Pharma is the go-to drug delivery expert for pharma customers worldwide, providing innovative drug delivery systems, components and active material science solutions across the widest range of therapeutic areas and delivery routes including nasal, pulmonary, ophthalmic, dermal and injectables. Aptar Pharma Services provide early stage to commercialization support to accelerate and derisk the drug development journey. Click here for more.


Video Spotlight: Lonza (Small Molecules)

  EXCLUSIVE ONLINE CONTENT

FREEZE-DRYING MICROSCOPY - Unravelling the Complexities of Freeze-Drying Pharmaceuticals With Advanced Microscopy Techniques

FREEZE-DRYING MICROSCOPY - Unravelling the Complexities of Freeze-Drying Pharmaceuticals With Advanced Microscopy Techniques

Paul Matejtschuk, PhD, Prof Yvonne Perrie, and Robert Gurney, PhD, say FDM is being used to analyze the most challenging formulations that require sophisticated stabilization methods. By altering and adapting the three main freeze-drying stages to specific formulations, researchers are providing the tools needed for the pharma industry to improve its drug development processes and maintain drug stability when scaling up to production.

Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK & Across Europe

Catalent Acquires Facility in Oxfordshire to Expand Biologics Capabilities in the UK & Across Europe

Catalent recently announced the acquisition from Vaccine Manufacturing and Innovation Centre UK Limited (VMIC Ltd.) of a biologics development and manufacturing facility currently under….

Medidata & Celsion Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

Medidata & Celsion Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

Celsion Corporation and Medidata recently announced they presented their findings on the use of a Synthetic Control Arm (SCA) in a completed Phase Ib dose-escalating study of GEN-1 in the neoadjuvant treatment of….

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of Drug-Enhanced Cell Therapy for the Treatment of Patients With Solid Tumors

Nurix Therapeutics Doses First Patient in Phase 1 Clinical Trial of Drug-Enhanced Cell Therapy for the Treatment of Patients With Solid Tumors

Nurix Therapeutics, Inc. recently announced the first patient has been dosed in its Phase 1 clinical trial of DeTIL-0255, a drug-enhanced tumor infiltrating lymphocyte therapy and….

  WHITEPAPERS & WEBINARS

Celanese Live Webinar: Engineering Drug Delivery to Improve Therapeutic Outcomes

Celanese Live Webinar: Engineering Drug Delivery to Improve Therapeutic Outcomes

Celanese and ThermoFisher Scientific have partnered together to present the value of the VitalDose® EVA drug delivery platform and manufacturing through Hot Melt Extrusion (HME) on September 9, 2021.

Where Do We Stand on Poorly Soluble Drugs and Peptides in Oral Delivery?

Where Do We Stand on Poorly Soluble Drugs and Peptides in Oral Delivery?

The Rule of 5 suggests that, for oral bioavailability, a better chance for oral absorption is obtained when the molecules are within the parameters of the Rule of 5’. However, the pharmaceutical industry is achieving oral efficacy with drugs that exceed….

Quotient Sciences: Upcoming Solubility Enhancement & Pediatric Development Webinars

Quotient Sciences: Upcoming Solubility Enhancement & Pediatric Development Webinars

Access our webinars on solubility strategies & pediatric drug development….

  WHITEPAPERS & WEBINARS

WHITE PAPER: Tackling a Changing Climate; Metered Dose Inhalers | Recipharm

WHITE PAPER: Tackling a Changing Climate; Metered Dose Inhalers | Recipharm

Are you prepared for the HFA phasedown? With many industries switching to more environmentally friendly propellants, pMDI developers need to be ready. Recipharm explore alternative technologies to HFA propellants, and how the devices and formulations can be optimized to ensure …

WHITE PAPER: HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity

WHITE PAPER: HPAPI Drug Solid Oral Dosage (SOD) Manufacturing – Ensuring Content Uniformity

What techniques should manufacturers employ when working with low-dose drug products?

By: Thomas Daggs, MBA, Vice President, Product Development & Quality Control, and Angelo Consalvo, Director of Manufacturing, Enteris BioPharma

Anyone who takes an oral tablet medication – whether prescribed …

New Opportunities for Oral Sustained Release Formulations With Polyvinyl Alcohol

New Opportunities for Oral Sustained Release Formulations With Polyvinyl Alcohol

 

Achieving the appropriate release kinetics for an active pharmaceutical ingredient (API) is essential to ensure success of the therapeutic. For example, for sustained release formulations, a consistent API dose over a prolonged period ensures that levels in the blood …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 20 – Inhalation Delivery
April 27 – Formulation Development